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ABSTRACT
The phosphorylation and desensitization of G-protein coupled receptors
involve several protein kinases. Two of the major ones are protein kinase A (PKA) and
protein kinase C (PKC). It has been reported that gravin, an A-kinase anchoring protein,
plays a role in regulating p2-adrenergic receptor desensitization, resensitization, and
internalization by recruiting both PKA and PKC, phosphatase, |3-arrestin, and clathrin to
the receptor. Similarities between the regulation of p-opioid receptor and p2-adrenergic
receptor suggest that a similar complex involving gravin may play a role in regulating popioid receptor signal transduction. To investigate this possibility, the current study
examined the distribution of gravin, p-opioid receptor and p2-adrenergic receptor in SHSY5Y cells as well as in AN3 CA cells cotrans fected with gravin and p-opioid receptor
or p2-adrenergic receptor vector constructs. This study also examined the distribution of
gravin, p-opioid receptor and p2-adrenergic receptor transgene in transfected AN3 CA
cells after the agonist stimulation. Our data showed that gravin is distributed along the
membrane of SH-SY5Y cells and partially colocalized with the p-opioid receptor and the
p2-adrenergic receptor. The gravin transgene was also concentrated along the membrane
of AN3 CA cells. Immunofluorescent microscopy showed extensive colocalization of
gravin and either the p-opioid receptor transgene or the p2-adrenergic receptor transgene
before agonist treatment. However, after agonist treatment, the p-opioid receptor and p2adrenergic receptor transgenes translocated from plasma membrane to a perinuclear
location, but there was no redistribution of grav in. The current study provided evidence
that the recombinant gravin and the receptor proteins were expressed and distributed in a
similar way as the native proteins. This validated their use in studying p-opioid receptor
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and p2-adrenergic receptor signal transduction and the role of gravin in regulating the
function of these receptors. The current study also provided evidence that gravin might
not interact with the receptors during the internalization of the receptors.

x

CHAPTER I

INTRODUCTION
The transduction of signals from the plasma membrane to specific subcellular
compartments is a complex and highly regulated series of events. In eukaryotes, protein
phosphorylation plays a crucial role in regulating these signaling events by modulating
the activity of specific signaling proteins. The i'amily of enzymes catalyzing the
phosphorylation of proteins, the protein kinases, represents a diverse group of proteins.
To date, more than 300 protein kinases have been found to play key roles in cellular
control and Hunter (1994) estimated that there are as many as 2000 conventional protein
kinase genes in the human genome. Within this structurely diverse family of intracellular
enzymes, the best understood is the cAMP-dependent protein kinase or protein kinase A.
Studies of cAMP-dependent protein kinase (PKA) activity provided the first clues about
the role of protein phosphorylation in the regulation of signal transduction (Walsh and
Van Patten, 1994).
The PKA holoenzyme is a heterotetramer composed of a regulatory (R) subunit
dimer that maintains two catalytic (C) subunits in a dormant state. Binding of cAMP to
tandom sites in each R subunit releases the active C subunits, which are then free to
phosphorylate substrates on serine or threonine residues. As the prototypic model of
intracellular kinases, PKA is a multifunctional enzyme with broad substrate specificity
(Taylor et al., 1990). Given that PKA is a soluble cytoplasmic enzyme and involved in
numerous signaling events, understanding the functional complexities of how the kinase
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is activated in the right place and at the right time inside the cell is important. This
specificity is achieved, in part, through the compartmentalization of PKA at different
subcellular locations through interactions with A-kinase anchoring proteins (AKAPs).
Compartmentalization of PKA was first shown in 1974, shortly after PKA was initially
purified and characterized (Beavor et al., 1974).
Eukaryotic cells express multiple forms of PKA regulatory and catalytic subunits,
which are termed RIa, Rip, Rlla, RIip, Ca, C|3, and Cy. These different subunits
assemble together as different PKA isoforms. The catalytic subunits show common
kinetic features and substrate specificity and therefore the characteristics of the PKA
holoenzymes are largely determined by the structure and properties of their regulatory
subunits. The R subunits are differentially distributed in mammalian tissues. RIa and
Rlla are ubiquitous, whereas Rip and RIip are expressed predominantly in endocrine,
brain, fat and reproductive tissues (Taylor et ah, 1992). The results of several studies
suggested that RI is predominantly in the soluble fraction, where as the majority of RII is
associated with the plasma membrane, cytoskeletal, secretory granule, Golgi, and nuclear
fractions (Joachim et ah, 1990; Pariset et ah, 1989; De Camilli et ah, 1986). In addition to
their distinctive expression and distribution, R subunits differ in their regulation and
biochemical properties. The binding affinity to cAMP of RIip in vivo is lower relative to
R lla and much lower compared to RIa (Taylor et ah, 1992). These data imply that
holoenzymes containing RI subunits or RII subunits (PKAI and PKAII) decode cAMP
signals that differ in duration and intensity: PKM is activated transiently by weak cAMP
signals, whereas PKAII responds to high and persistent cAMP stimulation. The
composition and specific biochemical properties of PKA isoenzymes account, in part, for
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differential cellular responses to discrete extracellular signals that activate adenylate
cyclase.
PKA Anchoring Proteins
It is now generally believed that PKA II is concentrated in particular subcellular
compartments through interactions with a family of A-kinase anchoring proteins
(AKAPs). AKAPs immobilize PKAII isoforms at specific intracellular locations by
binding RII subunits. Although most AKAPs preferentially bind to RII, several AKAPs
also bind to RI (Huang et al., 1997). The first PJI-binding proteins were identified as
contaminating proteins by co-purification with RII after affinity chromatography on
cAMP-Sepharose (Sarkar et ah, 1984). Currently, the standard method for detection of
AKAPs is an overlay assay which is a modification of the Western blot procedure (Carr
et ah, 1992). This assay is based on the observation that many, if not all, AKAPs retain
their ability to bind RII after they have been transferred to nitrocellulose (Lohmann et ah,
1984). Using this technique, a family of AKAPs ranging in size from 15 to 300 kDa has
been detected in a variety of tissues and cells (Carr et ah, 1992). A common feature of
AKAPs is that each anchoring protein contains two classes of binding sites: a conserved
“anchoring m otif’ which binds to the RII subunit of PKA and a “target domain” which
directs the subcellular localization of the “PKA-AKAP” complex through association
with structural proteins, membranes, or cellular organelles (Coghlan et al, 1993). Herberg
et ah (2000) showed by using surface plasmon resonance (SPR) that some AKAPs, such
as AKAP 79 and AKAP 84, bound both RII alpha and RII beta of PKA; however, the
affinity of the AKAPs for different R subunit isoforms differed.
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The PKA-AKAP complex model implies that AKAPs must contain a unique
targeting site that is responsible for association with subcellular structure. The targeting
domain is an essential feature of each AKAP because it determines specificity by
targeting the anchored PKA complex to particular organelles. So far, immuno
fluorescence microscopy and subcellular fractionation techniques have identified AKAPs
localized to centrosomes (AKAP 350) (Schmidt et al., 1999), the actin cytoskeleton
(AKAP 250, and AKAP 75/79/150) (Nauert et al., 1997; Coghlan et al., 1995), the
endoplasmic reticulum (AKAP 100) (McCartney et al., 1995), the Golgi (AKAP 85)
(Keryer et al., 1993), microtubules (MAP2) (Davare et al., 1999), mitochondria (sAKAP
84) (Lin et al., 1995), the nuclear matrix (AKAP 95) (Coghlan et al., 1994), the plasma
membrane (AKAP 15) (Tibbs et al., 1998), and peroxisomes (AKAP 220) (Schillace and
Scott, 1999). Although the proposed function of many AKAPs is to target PKA, several
AKAPs have been found to serve as scaffolds which simultaneously bind more than one
signaling protein and form a signaling complex consisting of enzymes with opposing
actions, such as kinases and phosphatases. For example, in neurons, AKAP 79 binds to
PKA, protein kinase C (PKC), and the protein phosphatase 2B (PP-2B) (Klauck et al.,
1996; Coghlan et al., 1995). The scaffold of AKAP 79 with PKA, PKC, and PP-2B
allows AKAP 79 to control the localization of two broad-specificity kinases and a
phosphatase. As distinct activation signals are presented at postsynaptic densities of
neurons, AKAP 79 might provide a point of convergence for multiple second-messenger
signals, such as cAMP, Ca2+, and phospholipids (Faux et al., 1996). Similarly, AKAP 220
has been shown to bind to protein phosphatase 1 (PP1) in addition to PKA (Schillace et
al., 1999), suggesting it functions to regulate kinase as well as phosphatase activity.
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Gravin
Gravin, also referred to as AKAP 250, is a kinase scaffold protein which binds to
both PICA and PKC. The carboxy-terminal fragment of gravin was originally identified as
a cytoplasmic antigen recognized by serum from a patient with myasthenia gravis
(Gordon et al., 1992). A series of in vitro binding experiments showed that the residues
1526-1780 of gravin bind to PKA with high affinity. Structural analysis of this region
indicated that it contained an amphipathic helical region similar to that found in other
AKAPs. The first 1000 residues of gravin are 69% identical to a murine mitogenic
regulatory gene, Src-supresssed C kinase substrate (SSeCKS)/ clone 72, which is a PKC
binding protein (Chapline et al., 1996), indicating that gravin may also be a PKC-binding
protein. This hypothesis was confirmed by Nauert et al. (1997), who demonstrated that
residues 265-556 of gravin bind to PKC in a pbosphatidylserine-dependent manner.
Gravin is expressed in many tissue and cell types. It is found in fibroblasts, and
smooth muscle cells in vivo, as well as in endothelial cells and several adherent tumor
cell lines in vitro (Grove et al., 1994). In human erythroleukemia cells, phorbol ester can
induce gravin expression. Gravin is also widely expressed in the nervous system. It has
been reported to be expressed in the cerebral cortex, in the molecular and granular layers
of cerebellum, in nerve bundles, in peripheral ganglia, and in sensory organs, such as
nerve fibers on the tip of the tongue and taste buds (Grove et al., 1994). Comparable to
gravin, SSeCKS is also widely distributed in the nervous system. Immunolabeling of
SSeCKS was found in the primary sensory neurons in the dorsal root ganglia, the dorsal
horn of the spinal cord, sensory ganglia, medulla, and the molecular layer of cerebellum.
This distribution is similar to that described for gravin in the nervous system (Siegel et
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al., 2001). Based on the observation that graviri is expressed in the nervous system and
evidence that this protein is a multivalent scaffold protein in signal transduction, it is
predictable that gravin might play a role in modulating the signaling events in the nervous
system.
Immunolocalization studies show that gravin is concentrated at the cell periphery
and is enriched in filopodia of erythroleukemia cells (Grove et al., 1994; Nauert et al.,
1997; Grove et al., 2001). In cultured human endothelial cells, gravin was not found to be
a component of stress fibers, microtubules or intermediate filaments, but associated with
the cell cortex, suggesting that gravin may be functionally related to either the plasma
membrane or the membrane skeleton (Grove et al., 2001). The wide distribution of gravin
further indicates that it is a multifunctional protein and regulates cellular events that
involve plasma membrane, possibly by anchoring PKA and PKC to specific sites at the
plasma membrane and coordinating phosphorylation and dephosphorylation in signal
transduction pathways. A recent study has shown that gravin and PKA forms a dynamic
complex with (32-adrenergic receptors (Shih et al., 1999). The gravin/receptor complex
includes PKC, protein phosphatases 2A and 2B, G protein coupled receptor kinase-2, Parrestin and clathrin (Lin et al., 2000). These complexes may be physiologically
important, since gravin deficiency has been reported to inhibit agonist-induced
internalization and resensitization of P2-adrenergic receptors (Shih et al., 1999).
G protein-Coupled Receptors
It is well accepted that neurons communicate by secreting neurotransmitters that
bind to specific receptors on postsynaptic cells. A major group of receptors involved in
neuronal signaling are the G-protein coupled receptors (GPCRs). More than a thousand
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members of this receptor family have been identified. A broad spectrum of extracellular
signals, including hormones, neurotransmitters, odorants and light, are detected by Gprotein coupled receptor family.
All GPCRs possess seven putative transmembrane domains, and convert
extracellular signals into intracellular signals by activating heterotrimeric G-proteins, a
protein complex consisting of an a-subunit which carries the guanine-nucleotide binding
site, and P- and y-subunits which form a tightly' bound dimer. In response to ligand
binding, GPCRs are converted into an active form which functions as a GDP/GTP
exchange factor and promotes the exchange of GDP for GTP on the a-subunit. This leads
to dissociation of the a-subunit from the GPy-dimer, and subsequent activation of Gprotein effectors such as ion channels, adenylyl cyclase, or phospholipase C. There are
three major types of GPCRs, based on the type of a G-protein they are coupled to and
their effect on second messenger signaling. One type of GPCR, (e.g. a-adrenergic
receptor) couples to an inhibitory Ga protein and inhibits adenylyl cyclase activity. This
results in a decrease in cAMP level and a decrease in PKA activity. Another type of
GPCR, (e.g. P2-adrenergic receptor) couples to a stimulatory Ga protein and activates
adenylyl cyclase. This results in increased cAMP levels and enhanced PKA activity. The
third group of GPCRs couple to Ga proteins which activate phospholipase C and in turn
activate PKC.
Chronic stimulation of GPCRs provokes attenuation of the receptor-mediated
signal, or desensitization. Desensitization is an adaptive mechanism in biological systems
thought to facilitate responsiveness of the cell to successive multiple extracellular stimuli.
For GPCRs, desensitization is a multistep process. The receptor is first uncoupled from
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the G-protein and receptor function is attenuated (Lohse et al., 1995). This step involves
phosphorylation of the receptor by several kinases, such as PKA, PKC, or G-protein
coupled receptor kinases. The phosphorylated receptor is then sequestered from the
plasma membrane to an intracellular compartment, where the receptor is
dephosphorylated by specific phosphatases and resensitized (Pitcher et al., 1995). When
the stimulation is chronically persistent, the receptor is down-regulated through protein
degradation and decreased transcription leading to a decrease in receptor number
(Handcock et al., 1988).
Two major patterns of rapid desensitization have been characterized. Agonistspecific or homologous desensitization refers to the situation in which receptor activation
by the agonist leads to desensitization of the same receptor type. This type of
desensitization involves mainly G-protein coupled receptor kinases (Inglese et al., 1993).
Heterologous desensitization refers to the situation in which receptor stimulation by the
agonist attenuates the response of other receptor types. Heterologous desensitization is
believed to result from activation of PICA and PKC, which in turn phosphorylates the
heterologous receptors.
Role of Gravin in Regulating G-protein Coupled Receptor Function
The desensitization of GPCRs has been particularly well studied in the 02adrenergic receptor/ PKA system. Exposure of 02-adrenergic receptors to the
catecholamines epinephrine or norepinehrine causes rapid desensitization of the receptorstimulated adenylyl cyclase response. Phosphoiylation of the receptor is the first step in
desensitization and occurs over a few minutes after agonist exposure (Benovic et al.,
1988). Primarily two kinase activities have been implicated in this agonist-induced
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phosphorylation: PKA (Clark et ah, 1989) and (32-adrenergic receptor kinase (Lohse et
al., 1990). Early studies on phosphorylation of P2-adrenergic receptor also indicated that
P-arrestin is an essential cofactor of P2-adrenergic receptor kinase (Loshe et al., 1990).
Interestingly, in A431 cells, although suppression of PKC has been reported to potentiate
rather than to attenuate agonist-induced desensitization (Shih et al., 1994), PKC is
required for the association of PKA and P-arrestin with the p2-adrenergic receptor (Shih
et al., 1999; Lin et al., 2000). This suggests that PKC might also play a role in P2adrenergic receptor desensitization, but in a manner that differs from that for PKA and
P2-adrenergic receptor kinase, which directly phosphorylate the receptor.
Although the mechanism of desensitization of P2-adrenergic receptor has been
well studied, the desensitization of another important group of GPCRs, the opioid
receptor family, is still controversial. Three major types of opioid receptors, p, 8 and k ,
have been identified by selective radioactive ligand studies (Chang et al., 1979). Through
the use of cloning techniques, the molecular events involved in regulating the activity of
these 3 opioid receptor types have been studied in detail. Although each of these
receptors has a distinct regional distribution within the brain and unique pharmacological
and physiological properties, the primary structures of these receptors show a 65-70%
homology with each other (Chen et al., 1993a). All of the three types preferentially
activate inhibitory G-proteins (Johnson et al., 1994; Law et al., 1994; Xie et al., 1994),
and are capable of regulating the same second messengers. Activation of these receptors
also increases phospholipase C activity (Ueda et al., 1995), causes a transient increase in
the levels of intracellular Ca2+ (Spencer et al., 1997), activates inwardly rectifying K
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channels (Henry et al., 1995), and stimulates the mitogen-activated protein kinases Erk-1
and Erk-2 (Fukuda et al., 1996).
Like (32-adrenergic receptor, the activities of the opioid receptors are attenuated by
chronic agonist treatment. Several researchers have reported agonist-induced opioid
receptor phosphorylation (Arden et al., 1995; Pei et al., 1995), with some suggesting that
phosphorylation correlates with agonist-induced receptor desensitization. This is
supported by site-specific mutagenesis studies. Replacement of Thr393 by Ala was
shown to blunt DAMGO-induced p-opioid receptor desensitization (Pak et al., 1997),
while El Kouhen and coworkers found phosphorylation on Ser363, Thr370, and Ser375 at
the COOH-terminus plays a role in modulating agonist-induced internalization of the popioid receptor (El Kouhen et al., 2001). Phosphorylation by PKA is unlikely the
mechanism of agonist-induced desensitization because the opioid receptor mediates
inhibition of cAMP formation. On the other hand, it has been reported that
phosphorylation by PKC modulates desensitization of the 5-opioid receptor (Ueda et al.,
1995) in a Xenopus expression system, whereas phosphorylation by PKC Ca2+ /
calmodulin-dependent protein kinase II (CaM kinase II) (Mestek et al., 1995), and
mitogen-activated protein kinase (Polakiewicz et al., 1998) modulates desensitization of
the p-opioid receptor. Studies on dominant negative mutants suggest that desensitization
of the 5-opioid receptor may also involve phosphorylation of the receptor by one or more
G protein-coupled receptor kinases (Pei et al., 1995). Other studies have been unable to
establish a causal relationship between receptor phosphorylation and desensitization. Loh
and coworkers compared the rate of p-opioid receptor phosphorylation and the rate of
DAMGO-induced receptor desensitization and they found that agonist-induced receptor
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phosphorylation occurred within minutes, whereas the desensitization of the receptor
took hours (Kouhen et al., 1999). The absence of correlation between receptor
phosphorylation and desensitization was further demonstrated by using p-opioid receptor
mutants in which all the putative phosphorylation sites were removed and receptor
phosphorylation was completely abolished. Interestingly, these receptor mutants could
still be desensitized by chronic exposure to agonist (Capeyrou et al., 1997). Thus, these
experiments suggest that receptor phosphorylation is not a prerequisite for
desensitization.
Receptor internalization is another mechanism for regulating the receptor. Rapid
internalization has been demonstrated in both the P2-adrenergic receptor system and the
opioid receptor system. Internalization of the receptor involves clathrin-dependent
endocytosis and happens rapidly after agonist stimulation (Gagnon et al., 1998). In the Padrenergic receptor system, the P2-adrenergic receptor kinase was found to colocalize
with the receptor several minutes after agonist stimulation, indicating its role in agonistinduced receptor internalization (Ruiz-Gomez et al., 1997). Internalization of the receptor
has also been reported to involve translocation of phosphoinositide 3-kinase to the plasma
membrane, and this process is mediated by P-adrenergic receptor kinase in an agonistdependent manner (Sathyamangla et al., 2001), suggesting phosphorylation may play a
role in the P2-adrenergic receptor internalization. P-Arrestin, a cytoplasmic cofactor of
p2-adrenergic receptor kinase, acts as an adapter protein which binds to clathrin (Lin et
al., 1997) and plays a role in targeting the receptors to clathrin-coated pits (Krupnick et
al., 1997).
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Phosphorylation may play a role in agonist-induced opioid receptor
internalization. Truncation of a Ser/Thr-rich domain unique to the C-terminus of p-opioid
receptor results in a significant inhibition of internalization and recycling of the receptor
(Segredo et al., 1997), suggesting the importance of phosphorylation at the C-terminus in
opioid receptor internalization. In addition, the rapid internalization of human 8-opioid
receptor could be blocked by a G protein-coupled receptor kinase inhibitor (Hasbi et ah,
2000). In vitro studies involving the use of either mutant receptors or kinase inhibitors
have found that phosphorylation by PKC regulates internalization of both p-opioid
receptor (Ueda et ah, 2001) and 8-opioid receptor (Xiang et ah, 2001). These
observations indicate the importance of G protein-coupled receptor kinase and PKC in
modulating internalization of opioid receptors. As in P2-adrenergic receptor trafficking,
internalization of opioid receptor is (3-arrestin-clependent and clathrin-dependent (Zhang
et ah, 1999; Xiang et ah, 2000), suggesting the similarities between the mechanism of P2adrenergic and opioid receptor internalization.
Recent studies have revealed that members of the AKAP family may play a role
in the regulation of GPCR function by recruiting various protein kinases, phosphatases,
and other proteins such as p-arrestin or clathrin to the receptor. Fraser et ah (2000)
reported that AKAP79 enhances down-stream activity of the MAP kinase pathway by
facilitating cAMP-induced phosphorylation of p2-adrenergic receptor following agonist
stimulation. A recent study has also reported that AKAP79 regulates the ability of Gprotein coupled receptor kinase 2 to phosphorylate the agonist-occupied receptors (Cong
et ah, 2001). Besides AKAP79, Malbon and his group have demonstrated that gravin may
serve a role as a kinase scaffolding protein that regulates p2-adrenergic receptor
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signaling. Gravin binds to both PKA and PKC, and associates with P2-adrenergic receptor
(Shih et al., 1999), suggesting that gravin is involved in desensitization of the receptor.
This complex also includes protein phosphatase 2B, which suggests that gravin is
involved in resensitization of the receptor (Shih et ah, 1999). Further investigation
indicated that gravin was essential to the organ ization of the signaling complexes
composed of the receptor, protein kinases / phosphatases, p-arrestin, and clathrin (Lin et
ah, 2000). Suppression of the expression of gravin by antisense oligodeoxynucleotides
blocked the association of the p2-adrenergic receptor with these proteins and the
sequestration and resensitization of p2-adrenergic receptor. Fan et ah (2001) have further
reported that the cytoplasmic C-terminus of the P2-adrenergic receptor contains the
gravin binding site and the interaction of gravin with the P2-adrenergic receptor is
maintained as the receptor is internalized. These observations suggest that gravin is
essential for desensitization of P2-adrenergic receptor by mediating phosphorylation and
internalization of the receptor.
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Statement of Problems
The cellular response to hormone or neurotransmitter application via G proteincoupled receptors is a highly regulated event and has been well studied in the p2adrenergic receptor system. The formation of a macromolecular complex composed of
gravin, p2-adrenergic receptor, several protein kinases/phosphatases, P-arrestin, and
clathrin suggests that gravin plays an important role as a scaffold for these protein-protein
interactions in p2-adrenergic receptor signal transduction. Studies on desensitization and
resensitization of the p-opioid receptor also provide evidence that p-opioid receptor
signaling is regulated by protein kinases and displays arrestin- and clathrin-dependent
internalization in response to agonist exposure. This raises the possibility that a complex
similar to that associated with p2-adrenergic receptor may associate with p-opioid
receptor after a signaling molecule binds. Gravin has been found widely distributed in the
sensory nervous system, where large amounts of opioid receptor are expressed.
Therefore, it is possible that gravin may play a role in regulating p-opioid receptor
signals in the nervous system. Based on this information, my hypothesis is that gravin
interacts with p-opioid receptor during agonist-induced internalization of the receptor. To
investigate this hypothesis, the first aim was to determine if gravin codistributed with popioid receptor. This aim was pursued by examining gravin expression and distribution in
SH-SY5Y cells, a neuroblastoma cell line that expresses p-opioid receptor when treated
with phorbol esters or retinoic acid (Pahlman el al., 1981 & 1984; Zadina et ah, 1993)
and in AN3 CA cells cotransfected with gravin and p-opioid receptor vector constructs.
The second aim of this study was to determine if agonist-induced internalization was
accompanied by redistribution of gravin. This aim was pursued by 1) generating full-
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length gravin and p-opioid receptor expression vectors and expressing these constructs in
AN3 CA cells, a cell line that does not express gravin or p-opioid receptors and 2)
examining the distribution of the gravin and p-opioid receptor transgenes after the cells
were treated with specific agonist.

CHAPTER II

MATERIALS AND METHODS
Materials
Eukaryotic and Bacterial Cell Culture
Eukaryotic Cell Lines
Human neuroblastoma cell line (SH-SY5Y) was a generous gift from Dr. Sandra
Roerig; human endometrial carcinoma cell line (AN3 CA) was obtained from ATCC
(American Type Culture Collection), Manassas, VA.
Eukaryotic Cell Culture and Transfection
Dulbecco’s modified Eagle’s medium (DMEM) containing L-glutamine,
lipofectAMINE (2 pg/ml) reagent and Opti-MEM reduced serum medium from Gibco
BRL, Life Technologies, Gaithersburg, MD. Fetal bovine serum (FBS) from Atlanta
Biological, Atlanta, GA. Penicillin-streptomycin, trypsin-EDTA (0.05% trypsin), alltrans retinoic acid (RA), isoproterenol, Tyr-D-Ala-Gly-MePhe-Gly(ol)-enkephalin
(DAMGO) from Sigma Chemical Company, St. Louis, MO.
Bacterial Cell Line
E. coli strain TOP 10F’ used to maintain and propagate plasmid vectors from
Invitrogen, Carlsbad, CA. SOC medium was included in the kit.
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Bacterial Cell Culture and Transformation
Bacto™ Yeast Extract and Tryptone Peptone from Becton Dickinson, Sparks, MD.
Selected agar from Gibco BRL, Life Technologies. Ampicillin (sodium salt) from Sigma
Chemical Company, St. Louis, MO.
Oligonucleotides
The primers used to perform RT-PCR reactions were designed by Dr. Bryon
Grove and purchased from Genosys, St. Louis, MO. The sequences of these
oligonucleotides are shown in Table 1.
Vectors
pcDNA 3.1.V5/His-A and pCR.2.1 from Invitrogen. Expression vector GR815534 (gravin expression vector) was designed by Dr. Bryon Grove and constructed by
Magdalena Walkiewicz. This expression vector' was generated by inserting a full-length
gravin sequence (nt 81to 5534) into the multiple cloning site of the pcDNA 3.1.V5/His-A
vector in frame with the V5 and polyhistidine tags. Expression vector
pcDNA3.1.V5.TGA was designed by Dr. Bryon Grove and constructed by inserting an
18 base pair linker containing a stop codon (TGA) into the Age I site of the pcDNA
3.1.V5/His-A vector.
Enzymes
The restriction endonucleases and other enzymes used in this study include: Age I,
BamH I, BstB I, BstE II, Dde I, EcoR I, EcoR V, Hind III, Kpn I, Nhe I, Not I, Sty I, Xba
I, T4 DNA ligase from New England Biolabs, Beverly, MA. Advantage-GC cDNA
polymerase from Clontech, Palo Alto, CA. PfuTurbo DNA polymerase from Stratagene,
La Jolla, CA. AMY reverse transcriptase from Promega, Madison, WI.

Table 1. Oligonucleotides Used for Cloning Techniques.

Oligonucleotide

Sequence

Additional Restriction
Enzyme Sites for Cloning

Desired Function

MOR4

TAATGGTACCTCCGCCTGACGCTCCTCTC

Kpn 1

Forw ard Prim er for M O R clon e

MOR2

AAAATCTAGAGGGGCAACGGAGCAGTTTCTG

Xba 1

R e v e rse Prim er for M O R clone

MOR3

CAGAGTGGCCAGAGAGGAAAGAGGT

R T P rim er for M O R clone

b e ta a d re n o l

AAGGGGTACCACACCACAGCCGCTGAA

Kpn 1

hgfooH ronrvQ

G C C C I C T A G A T A .G C A G T G A G T C A T T T G T A C T

o 11
/Y\ LK/ U

betaadreno3

CTGCTCCTCAAATCCCTGCC

B etaad reno5

CTGTTTAGTGTTCTGTTGGGCGGGGGG

Forw ard Prim er for p 2- A R clon e
R e v e rse P rim e ri for p 2-A R cion e
R T P rim er for p 2- A R clone
R e v e rse Prim er2 for p 2-A R clon e
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Reverse Transcription and Polymerase Chain Reaction
RNA STAT-60™ kit used to purify mRNA from cultured cells from TEL-TEST,
Inc., Friendswood, TX. RNase inhibitor from Promega, Madison, WI. Deoxynucleotide
Mix (dNTPs) from Brinkmann Instruments, Inc., Westbury, NY. All polymerase chain
reactions were performed on a Thermal Cycler from Perkin-Elmer Corp., Foster City,
CA.
DNA purification
DNA fragments were purified from 1% agarose gel using a QIAquick Gel
Extraction Kit from Qiagen, Inc., Valencia, CA. Circular DNA from small bacterial
cultures was purified using either a Plasmid Mini Kit from Qiagen, or phenol-chloroform
purification including phenol, chloroform, isopropanol from Sigma and isoamyl alcohol
from Fisher Scientific Company, Fairlawn, NJ. Circular DNA from large bacterial
cultures was purified using an EndoFree Maxi Kit from Qiagen, Inc. DNA and RNA
concentration was measured on a UV spectrophotometer from Dr. Ann Flower.
Gel Electrophoresis
Agarose and ethidium bromide from Gibco BRL, Life Technologies.
Acrylamide, bis-acrylamide and sodium dodecyl sulfate (SDS) from Bio-RAD
Laboratory, Hercules, CA. Ammonium persulfate (APS), bromophenol blue, N,N,N’,N’tetramethylethylenediamine (TEMED) from Si gma. Gel documentation included
capturing image of the gel using a UVP High Performance Ultraviolet Transilluminator
from Ultra Violet Products, Upland CA.
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Immunoblotting and Protein Assays
Protease inhibitors used to lyse cells include: aprotinin, calpain inhibitor,
ethylenediamine-tetraacetic acid (EDTA) disodium salt, pepstatin A, and
phenylmethylsulfonyl fluoride (PMSF) from Sigma.
BCA protein assay kit from Pierce, Rockford, IL.
Nitrocellulose membrane from Bio-RAD. Proteins immobilized on membrane
were detected using the CDP-Sta/5 detection system from Applied Biosystems, Bedford,
MA. This kit includes I-Block™ reagent and 0.25mM Chemiluminescent Substrate.
Immunofluorescence and Confocal Microscopy
Paraformaldehyde was purchased from Polysciences, Inc., Warrington, PA.
Normal goat serum and digitonin were purchased from Sigma. FITC-guard mounting
medium was purchased from Testog Inc., Chicago, IL. The slides were observed on
either a Nikon TE 300 inverted Epi-fluorescence Microscope (Filters: ex580 nm and
em620 nm for Cy3, ex480 nm and em535 nm for FITC; Dichroic mirror: 595 nm for Cy3
and 505 nm for FITC) equipped with Hamamatsu “ORCA” digital camera from Dr.
Mickael Atkinson or a Fluoview 300 laser scanning confocal system coupled to a 1X70
Olympus inverted Epi-fluorescence microscope equipped with Argon laser for FITC and
“HeNe” laser for Cy3 from Dept, of Anatomy & Cell Biology.
Antibodies
Monoclonal mouse anti-gravin antibody 2B3-1.1 and polyclonal rabbit antigravin antibody Rb7753 were obtained from Dr. Bryon Grove. Monoclonal mouse antiV5 antibody was obtained from Invitrogen Coloration, Carlsbad, CA. Polyclonal rabbit
anti-(32-adrenergic receptor antibody was obtained from Santa Cruz Company, Santa
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Cruz, CA. Polyclonal rabbit anti-p-opioid receptor antibody was from Neuromics,
Minneapolis, MN. Cy3-conjugated Donkey anti-mouse IgG antibody and FITCconjugated Donkey anti-rabbit IgG antibody were obtained from Jackson
ImmunoResearch Laboratories, Inc.. Alkaline phosphatase (AP)-conjugated anti-mouse
IgG and AP-conjugated anti-rabbit IgG were obtained from Sigma.
Other Chemicals
Bis [2-hydroxyethyl] imino-tris [hydroxymethyljmethane (Bis-Tris), benzamidine
hydrochloride, bovine serum albumin (BSA), calcium chloride (CaCh), dimethyl
sulfoxide (DMSO), glycerol, magnesium chloride (MgCh), (3-mercaptoethanol,
potassium phosphate, sodium chloride (NaCl), sodium phosphate (dibasic) (Na2HP0 4 ),
sodium phosphate (monobasic, anhydrous) (NaH2P0 4 ), Tris (hydroxymethyl)aminomethane (Trizma Base), Triton X-100 from Sigma Chemical Company, St. Louis,
MO. Sodium hydroxide (NaOH), hydrochloric acid (HC1) from Fisher Scientific
Company, Fairlawn, NJ. Tween-20 from Bio-RAD Laboratory, Hercules, CA. Imidazole
from Acros Organics, NJ. Reagent grade water was generated using a Milli-Q water
purification system, Millipore Corporation, Bedford, MA.
Methods
Eukaryotic Cell Culture
Human SH-SY5Y cells and human AN3 CA cells were maintained in minimum
essential DMEM containing 10% fetal bovine serum, 100 units/ml penicillin, and 100
pg/ml streptomycin in a humidified 5% CO2 incubator at 37 °C. Fresh medium was
added to the culture every 2-3 days and the cells were passaged when confluent.
Retinoic Acid Treatment
SH-SY5Y cells were incubated until the cells were 70-80% confluent. Ten pM
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all-trans retinoic acid was added to the culture medium and cells were incubated for 6
days before staining or lysing.
Agonist Treatment
AN3 CA cells seeded on glass covers! ips were either co-transfected with GR815534/pcDNA3.1.MORl.V5 or transfected with GR81-5534 or pcDNA3.1.MORl.V5
alone. The cells were then subject to 5 pM DAMGO for 30 min.
For isoproterenol treatment, AN3 CA cells were either co-transfected with
GR81-5534/pcDNA3.1.p2-AR.V5 (or pcDNA3.1. P2-AR) or transfected with GR81-5534
or pcDNA3.1.p2-AR.V5 (or pcDNA3.1. p2-AR) alone. The cells were exposed to 10 pM
isoproterenol for 30 min.
Cloning Techniques
Generating PCR Product
Generating Diethvlpvrocarbonate (DEPC1 Water. 500pl of DEPC was mixed
with 500 ml of Milli-Q water by shaking thoroughly. The DEPC mixed water was stored
at RT overnight and then autoclaved for 20 minutes in a liquid cycle.
Purification of mRNA from retinoic acid treated SH-SY5Y cells. Following
treatment with retinoic acid (lOpM) for 6 days, SH-SY5Y cells grown in monolayer in
25cm2 flasks were lysed in the culture dish by adding 2 ml of the RNA STAT-60™ and
passing the cell lysate several times through a pipette. The homogenate was stored at RT
for 5 minutes to permit the complete dissociation of nucleoprotein complexes, then
transferred to a microcentrifuge tube and mixed vigorously with 0.4 ml chloroform.
Following incubation at RT for 2 min, the mixture was centrifuged at 12,000x g for 15
minutes at 4°C and the upper aqueous phase was collected into a fresh tube. To
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precipitate the mRNA, 1 ml of isopropanol was added to the collected phase. The sample
was stored at RT for 10 minutes, and then centrifuged at 12,000x g for 10 minutes at 4°C.
The RNA pellet was washed with 1 ml of 75% ethanol, air dried and dissolved in 50 pi of
DEPC water.
Reverse Transcription. Reverse transcription was performed on 1 pg of mRNA
using 10 nM of each of the reverse transcription primer (MOR3, corresponding to the 3’
non-coding region of the published human MORI; or betaadreno3, corresponding to the
published human p2-adrenergic receptor). For each reaction, 1 pg of mRNA and 1 pi (10
nM) of the primers were mixed in 3 pi DEPC EEO, heated in a water bath at 72 °C for 5
minutes, and then incubated on ice for 5 minutes. The mixture was combined with 0.5 pi
(20 U) AMV reverse transcriptase, 0.25 pi (20 U) RNase inhibitor, 1 pi dNTP, and 2 pi
5X AMV reverse transcriptase buffer, and then the desired amount of DEPC H2O was
added to the mixture to bring the volume to 10 ul. The reaction was performed in a water
bath at 45 °C for one hour.
Polymerase Chain Reaction. PCR reactions were performed in thin-walled
500 pi micro-reaction tubes in a Perkin-Elmer thermal cycler. The components of each
reaction in a 50 pi volume are listed in Table 2. Reaction mixtures were overlaid with one
drop of mineral oil to reduce refluxing. The program used for all PCR reaction was as
follows: (1) 94 °C for 30 seconds; (2) 35 cycles in which each cycle consisted of a 1
minute 94 °C denaturation step and a 3 minute 6 8 °C (70 °C for the second p2-AR clone)
annealing and elongation step; (3) 3 minute 6 8 °C (70 °C for the second p2-AR clone)
extension step. Following amplification, 10 pi of the PCR products was analyzed by
submerged agarose gel electrophoresis using a 1% agarose gel.

Table 2. PCR Reactions* Performed in Cloning Technique.

Sequence to
be Amplified

Template

Forward
Primer

Reverse
Primer

MORI

R T p ro d u c t p rim e d
w ith M O R 3

M OR4
(1 0 n M )

M OR2
(1 0 n M )

A d v a n ta g e -G C cD N A
p o ly m e ra se
w ith su p p lie d 5 X b u ffe r

A 1381 b p fra g m e n t fro m h u m a n M O R se q u en c e

P 2 -A R

R T p ro d u c t p rim e d
w ith b etaa d re n o 3

b e ta a d re n o l
(1 0 n M )

b e ta a d re n o 2
(1 0 n M )

P fu T u rb o D N A
p o ly m e ra se * *
w ith su p p lie d 10X b u ffe r

A 1358 b p fra g m e n t fro m h u m a n p 2-A R se q u en c e

P2-A R

R T p ro d u c t p rim e d
w ith b etaa d re n o 3

b e ta a d re n o l
(1 0 n M )

b eta a d re n o 5
(1 0 n M )

A d v a n ta g e -G C cD N A
p o ly m e ra se
w ith su p p lie d 5 X b u ffe r

A 1422 b p fra g m e n t fro m h u m a n p 2-A R se q u en c e

Polymerase

Desired Product

* All reactions were performed in the presence of lpl of template, lpl of each primer, lpl of polymerase,
and 1pi of dNTP in a 50pl volume.
** PfuTurbo DNA polymerase was supplemented with 1pi of DMSO in this reaction.
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Generating Recombinant Protein Expression Vectors
Restriction Endonuclease Digestion. To generate the required overhangs for
ligation, the pcDNA3.1.V5.TGA vector and the MOR and the first P2-AR PCR products
were digested by Kpn I and Xba I (See Table 1). The reactions were performed using the
PCR product or 1 pg of pcDNA3.1.V5.TGA vector, 1 pi of Kpn I, 1 pi of Xba I, 1 pi of
10X NEBuffer 2, 1 pi of 1 mg/ml BSA in a 37 °C water bath for one hour. The second
p2-AR PCR was ligated into the pCR2.1 vector by TA cloning first, and then digested by
EcoR I. The pcDNA3.1.V5/Ehs was also digested by EcoR I to generate the overhangs
for ligation.
Gel Purification. To purify the appropriate DNA fragments, the digestion
products were separated electrophoretically on a 1 % agarose gel. The bands at the
appropriate sizes were excised using a clean razor blade and the DNA was purified from
the gel using a Q'lAquick Gel Purification Kit. Briefly, 3 volumes of Buffer QG
(solubilization buffer) was added to 1 volume cf gel and incubated at 50 °C until the gel
was dissolved. One volume of isopropanol was then added to the gel mixture and mixed.
The mixture was then applied onto a QIA quick spin column and centrifuged at 10,000x g
for one minute. After the flow through was discarded, 750 pi of Buffer PE (washing
buffer) was placed onto the column and centrifuged at 10,000x g for 1 min. Prior to
collecting the DNA, the flow through was discarded and the column was centrifuged for
an additional 1 min at 12,000x g. Thirty microliters of Milli-Q water was added onto the
column, the column was incubated with the water at RT for 1 min, and then the column
was centrifuged at 12,000x g for 1 min. The eluted DNA was collected in a clean 1.5 ml
microcentrifuge tube.
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Ligation. Following digestion, the MORI and the first P2-AR PCR products were
ligated into pcDMA3.1.V5.TGA using standard, procedures. The ligation reaction was
performed in a clean 1.5 ml microcentrifuge tube containing 1 pi of T4 DNA Ligase,
200 ng of the digested pcDNA3.1.V5.TGA vector, 40 ng of the digested PCR product, 2
pi of 10X T4 DN A Ligase buffer. The total volume of the reaction was brought up to 20
pi by Milli-Q water. The mixture was allowed to incubate in a waterbath at 14 °C
overnight. The second P2-AR insert sequence, which was excised from the pCR2.1 vector
(see above), was ligated into pcDNA3.1V5/His vector.
Analysis of Clones
Transformation of Competent Bacterial Cells
Frozen competent TOP 10F’ cells (50 pi) were thawed on ice, mixed gently with
3 pi of the ligation product and incubated on ice for 30 minutes. Following incubation,
the mixture was heated to 42 °C for 30 seconds before 250 pi SOC medium was added,
and the mixture was shaken at 225 rpm at 37 °C for one hour. For each transformation,
50 pi and 200 pi of the mixture were spread over the entire surface of 2 LB agar plates
containing 50 pg/ml ampicillin using a sterile, bent glass rod. The plates were then
inverted and incubated at 37 °C for 12-18 hours or until colonies appeared.
Selection of Colonies
Several 2. ml cultures containing LB broth and 50 pg/ml ampicillin were
inoculated with single colonies from the agar plate. The cultures were allowed to grow 8
hours or overnight at 37 °C while shaking at 225 rpm.
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Plasmid DNA Purification by Phenol-Chloroform
One and one-half ml of each of the ove rnight cultures was transferred to a
microcentrifuge tube and centrifuged at l,500x g for 10 min to pellet the cells. Following
centrifugation, the supernatant was discarded and each of the pellets was resuspended in
100 pi of solution I (50 mM glucose, 25 nM Tiis-Cl, 10 mM EDTA, pH 8.0). The
suspensions were then mixed by inversion with 200 pi of solution II (0.2 N NaOH, 1%
SDS) and incubated on ice for 5 min. One hundred and fifty pi of solution III (3 M
potassium acetate, 11.5 % glacial acetic acid) was then added to each mixture and the
solution were mixed by inverting the tube 4-5 times, placed on ice for 5 min, and
centrifuged at 12,000x g for 5 min. After centrifugation, the supernatants were transferred
to microcentrifuge tubes containing 500 pi phenol/chloroform solution (pH 8.0), mixed
by vortexing, and the mixtures were centrifuged for 2 min at 12,000x g. The upper
aqueous phases were transferred to microcentrifuge tubes containing 300 pi isopropanol,
mixed by vortexing, and centrifuged at 16,000x g for 15 min to pellet the DNA. The
supernatants were discarded and the pellets were washed with 1 ml of 75% ethanol by
centrifugation at 12,000x g for 5 min. The pellets were then air dried and dissolved in 50
pi Milli-Q water.
Screening for Positive Clones
Positive clones were screened for the presence of specific restriction enzyme sites.
For pcDNA3.1.MORl.V5, the restriction enzymes were EcoR I and Kpn I/Xba I. For
pcDNA3 .1 .p2-AR.V5 , the restriction enzymes used to screen for positive clones were
BstE II, EcoRV, and Kpn I/Xba I. For pcDNA3.1.P2-AR, the restriction enzyme used was
EcoR I. Restriction endonuclease digestion was performed in a water bath at the
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appropriate temperature for 1 hour in a 10 pi volume containing 2 pi of DNA of the clone
to be analyzed, 0.25 pi of each restriction enzyme, and 1 pi of the appropriatelOX
NEBuffer with or without 1 pi of 10X BSA. The sample was then analyzed by
submerged agarose gel electrophoresis using 1% agarose gel. Positive clones were
identified by the number of bands and their sizes.
Generating High-quality DNA Used for Diagnostic Analysis
Clones selected for further analysis were cultured overnight at 37 °C in 3 ml of
LB broth containing 50 pg/ml ampicillin while shaking at 225 rpm. The plasmid DNA
was purified using a QIAgen Plasmid Mini Kit to generate high-quality DNA. The
culture was centrifuged at l,500x g for 10 minutes and the bacterial pellet was
resuspended in 0.3 ml of Buffer PI (50 mM Tris-Cl, 10 mM EDTA, 100 pg/ml RNase A,
pH 8.0). After resuspension, the culture was mixed gently with 0.3 ml of Buffer P2 (200
mM NaOH, 1 % SDS) and incubated at RT for 5 min. 0.3 ml of Buffer P3 (3.0 M
potassium acetate, pH 5.5) was pre-chilled, then mixed immediately with the culture and
incubated on ice for 5 min. After incubation, the mixture was centrifuged at 16,000x g for
10 min. The supernatant was removed promptly, applied to a QIAGEN-tip 20, which was
equilibrated by 1 ml Buffer QBT (750 mM NaCl, 50 mM MOPS, 15 % isopropanol, 0.15
% Triton X-100), and allowed to enter the resin by gravity flow. The QIAGEN-tip 20
was then washed 4 times with 1 ml of Buffer QC (1.0 M NaCl, 50 mM MOPS, 15 %
isopropanol). The plasmid DNA bound to the resin was eluted by 0.8 ml of Buffer QF
(1.25 M NaCl, 50 mM Tris-Cl, 15 % isopropanol), and precipitated with 0.56 ml of
isopropanol by centrifugation at 16,000x g for 30 min. The DNA pellet was then washed
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with 1 ml of 75 % ethanol by centrifugation at 12,000x g for 5 min, air-dried for 5 min
and redissolved in 30 gtl of Milli-Q water.
Diagnostic restriction analysis
To confirm the presence and the orient ation of the insert DNA, diagnostic
restriction analysis was performed in a water bath at the appropriate temperature in
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pi

of reaction containing 2 pi of purified plasmid DNA, 1 pi of the appropriate restriction
enzymes and 1 pi of 10X NEBuffer with or without 1 pi of 10X BSA for one hour. The
restriction enzymes used for analyzing pcDNA3.1.MORl.V5 were BamHl, BstB I,
Hindlll/EcoR I, and Kpn I/Xba I. The restriction enzymes used for analyzing
pcDNA3.1.p2-AR.V5 were BstE II, Dde I, Sty 1, and Hind III/EcoR V. The restriction
enzymes used for analyzing pcDNA3.1 .P2-AR were EcoR V and Not I/BstE II. The
reaction products were then subjected to agarose gel electrophoresis using a 1 % agarose
gel.
DNA Maxi Prep
One hundred ml of LB broth with 100 pg/ml ampicillin was inoculated with 60 pi
of a fresh overnight culture of the selected clone and incubated in 37 °C for 12 hours
while shaking at 225 rpm. The bacterial cells were then harvested by centrifugation at
2,500x g for 15 min. The pellet was resuspended in 10 ml of Buffer PI (50 mM Tris-Cl,
10 mM EDTA, 100 pg/ml RNase A, pH 8.0), followed by gentle mixing with 10 ml of
Buffer P2 (200 mM NaOH, 1 % SDS) and incubation at RT for 5 min. Ten ml of pre
chilled Buffer P3 (3.0 M potassium acetate, pH 5.5) was then added to the lysate and
mixed by inverting the tube 4-6 times. The lysate was poured into the barrel of a
QIAfilter Cartridge and incubated at RT for 10 min. After the cap was removed from the
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QIAfilter outlet nozzle, the plunger was gently inserted into the QIAfilter Cartridge and
the cell lysate was filtered into a 50 ml tube. The filtered cell lysate was then mixed with
2.5 ml of Buffer ER and incubated at RT for 30 min. The solution was then applied to a
QIAGEN-tip 50, which was equilibrated by 10 ml of Buffer QBT (750 mM NaCl, 50
mM MOPS, 15 % isopropanol, 0.15 % TritonX-100), and allowed to enter the resin by
gravity flow. The QIAGEN-tip 50 was washed twice with 30 ml of Buffer QC (1.0 M
NaCl, 50 mM MOPS, 15 % isopropanol) and plasmid DNA was eluted with 15 ml of
Buffer QN (1.6 M NaCl, 50 mM MOPS, 15 % isopropanol). After elution, DNA was
precipitated by mixing with 10.5 ml isopropanol and centrifuging the mixture
immediately at 16,000x g for 30 min in a 50 ml endotoxin-free tube. The DNA pellet was
washed with 2.5 ml of endotoxin-free 75 % ethanol by centrifugation at 16,000x g for 10
min. The supernatant was removed and the pellet air dried and redissolved in 30 pi of
endotoxin-free Buffer TE (10 mM Tris-Cl, 1 mM EDTA). DNA concentration was
determined by UV spectrophotometry.
Transient Transfection
AN3 CA cells were seeded onto glass coverslips in an 8 -well plate at 2 x 105
cells/well and incubated for 18-24 hours in growth medium containing serum. For each
transfection, 1 pg of the vector DNA was mixed with 10 pg of lipofectAMINE™ reagent
in 195 pi of Opti-MEM reduced serum medium at RT for 30 minutes. While incubating
the mixture, the cells were rinsed 3 times with Opti-MEM medium. The DNA mixture
was then mixed with 800 pi Opti-MEM and applied to one well of an 8 -well plate. The
cells were incubated with the DNA/ LipofectAMINE complex at 37 °C for 5 hours. At
the end of the incubation, the DNA/ LipofectAMINE complex in Opti-MEM was
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replaced with complete growth medium containing serum and the cells were incubated at
37 °C for 45-48 hours.
Immunofluorescence Microscopy
Cells on glass coverslips were fixed with 3.7 % paraformaldehyde in PBS (58
mM Na2HPC>4 , 17 mM Nat^PCVKhO,

68

mM NaCl, pH 7.2) for 10 min, washed twice

with PBS 10 min per wash, permiablized with 62 pg/ml digitonin in PBS for 10 minutes,
and washed once more with PBS for 10 min. Following this, the cells were incubated in
5%NGS/0.1%BSA/PBS at RT for 30 min and then exposed to primary antibody diluted
in 1%NGS/0.1%BSA/PBS for one hour at 37 °C. After exposure to the primary antibody,
the cells were washed 3 times in PBS and incubated for one hour at 37 °C in secondary
antibody diluted in 0.1%BSA/PBS. The cells were then rinsed with PBS and the
coverslips were mounted on glass slides with FITC-guard and observed with either a
Nikon TE 300 inverted Epi-fluorescence microscope or a Fluoview 300 laser scanning
confocal system. For Nikon TE 300 inverted Epi-fluorescence microscope, the images
were collected with Matrox frame capture and analyzed with Metamorph software from
Universal Imaging Corp. For Fluoview 300 laser scanning confocal system, the images
were collected with photo multiplier tube (PMT) and analyzed with Fluoview software.
Cell Lvsis and Immncblotting Analysis
Preparation of Cell Lysate
Cells grown in 8 -well plates or 25 cm2 flasks were harvested by scraping and
washed twice by resuspending in PBS

(68

mM NaCl, 58 mM Na2HP0 4, and 17 mM

NaH2P0 4 , pH 7.2) and centrifuging at 1,500 rpm for 10 min. The cell pellet was
resuspended in lysis buffer (150 mM NaCl, 20 mM Tris base, 0.01 M EDTA disodium
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salt, 10 mM Benzamidine HCL, 1% Triton X-100, and 0.05% Tween-20, pH 7.4)
containing 100 pg/ml leupeptin and 1 mM PMSF and incubated on ice for 10 min. The
extract was then centrifuged at 16,000x g for 10 min at 4 °C and the supernatant was
collected.
BCA Protein Assay
The protein concentration in the cell lysate was determined using a BCA
(bicinchoninic acid) assay. The protein standard for the assay was prepared by mixing
200 pi of lysis buffer containing 5 mg/ml of bovine serum albumin (BSA) with 200 pi of
lysis buffer containing 10 pg/ml leupeptin to make a 2.5 mg/ml of BSA solution. The 2.5
mg/ml BSA solution was then diluted 8 times by serial dilution into 1.5 ml
microcentrifuge tubes containing 200 pi of lysis buffer with 10 pg/ml leupeptin. Samples
were prepared by mixing 5 pi of cell lysate with 45 pi of lysis buffer. Ten pi of each
mixture was then loaded into a 96-well plate by triplicate, mixed with 200pl of BCA
solution from the BCA protein assay kit. The sample and BCA reagent was allowed to
react for one hour at 60 °C. The absorption of each sample was measured at X5eo on a
plate reader and protein concentrations were calculated from the protein standard.
Western Blotting
After the amount of protein in the cell lysate was determined by the BCA
protein assay, cells lysates were mixed with appropriate volumes of sample buffer (0.5 M
Tris, 10 % SDS, glycerol, P-mercaptoethanol, bromophenol blue) to ensure that the total
protein in each sample was the same. Samples were then electrophoresed on 5% SDSpolyacrylamide gels using 20 mA constant current for 1-1.5 hour and transferred
electrophoretically to a nitrocellulose paper usingl50 mA constant current for 2 hours in
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transfer buffer (192 mM glycine, 25 mM Tris, 20 % methanol). After 1 hour to overnight
incubation in the blocking buffer (0.2 % I-Block™ Reagent, 0.1 % Tween®-20, PBS),
the blot was incubated with either an anti-V5 antibody diluted 1:5000 or a polyclonal
anti-gravin antibody diluted 1:1000 at RT for 1 hour. The blot was then washed with PBS
4 times for 5 minutes and incubated with an alkaline phosphatase conjugated secondary
antibody diluted 1:100,000 at RT for 1 hour, followed by washing with PBS 4 times for 5
minutes. All antibodies were diluted in blocking buffer. For detection, the blot was rinsed
in IX Assay buffer (20 mM Tris, 1 mM MgCk, pH 9.8) twice for several seconds and
exposed to substrate solution (CDP-,Sta/'s>substrate) for 5 min. The blot was then exposed
to a standard X-ray film for 1-5 min and the film was developed in a MOHRpro
processor.
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CHAPTER III

RESULTS
Expression and Distribution of Gravin in SH-SY5Y Cells
Western blot and immunofluorescent microscopy revealed that treatment of SHSY5Y cells by retinoic acid significantly increased gravin expression. As shown in
Figure 1, anti-gravin antiserum strongly detected a -300 kDa band on immunoblots of
extracts from cells treated with 10 mM retinoic acid (RA) for 8 days, but did not detect a
band in extracts from untreated cells and only v/eakly detected a band in extracts from
cells treated with ethanol, the solvent used to dissolve the retinoic acid. The -300 kDa
band in the RA treated cells was consistent with the molecular mass of gravin previously
found (Grove et al., 1994). The band at -250 kDa was likely a proteolytic fragment of
gravin. Because the protein concentration in the cell extracts was determined by BCA
protein assay and an equal amount of protein was loaded into each lane, differences in the
density of the bands indicated that the cells treated by RA for 8 days expressed higher
levels of gravin than untreated cells and ethanol control cells. Figure 2 illustrates the
results of a time course experiment in which SF1-SY5Y cells were exposed to RA for
various times before they were harvested and equal amounts of total protein were
subjected to SDS-PAGE. According to Figure 2, gravin level in the cells started to
increase after 4 days of treatment with RA, reached the highest level after 6 and
treatment and then decreased at

10

and

12

days of treatment.
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8

days of
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The effect of RA on gravin expression was confirmed by immunofluorescence
microscopy. Cells treated with RA showed a higher level of fluorescent staining than
observed in untreated cells (Fig 3). Immunofluorescence microscopy also revealed that
gravin was localized primarily at the surface of the cell bodies and the cellular processes
(Fig 4). The RA treated cells were also double labeled for gravin and p-opioid receptor
(MOR) and observed using confocal microscopy. Both the anti-MOR antiserum and the
anti-gravin antibody detected not only membrane staining, but also partial cytoplasmic
staining; however, the anti-gravin antibody detected primarily membrane staining. By
image merging, there was partial colocalization of gravin and MOR (Fig 5A). Similarly,
in cells double labeled with anti-P2-adrenergic receptor (P2 -AR) and anti-gravin
antibodies, the anti-P2-AR antibody detected both membrane staining and cytoplasmic
staining, and image merging showed partial colocalization of gravin and P2-AR (Fig 5B).
In order to investigate whether the agon ist-induced internalization of the MOR or
P2-AR was accompanied by redistribution of gravin, SH-SY5Y cells were treated with
either DAMGO for 60 min or isoproterenol for 30 min. There was no redistribution of
either the receptors or gravin in these cells (data not shown).
Characterization of Receptor Expression Vectors
To investigate the interaction of gravin and recombinant MOR and P2-AR in
transfected AN3 CA cells, the expression vectors, pcDNA3.1.MORl.V5, pcDNA3 .1 .p2AR.V5, and pcDNA3.1.p2-AR were generated by inserting MOR and P2-AR sequences
into either pcDNA3.1.V5/His or a modified pcDNA3.1.V5.TGA vector.
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Characterization of PCR products
Agarose gel electrophoresis of PCR products generated using receptor specific
primers revealed the presence of DNA fragments which corresponded in size to the
predicted size of 1381, 1358 and 1422 bp for the MOR insert, the first p2-AR insert and
the second p2-AR insert, respectively (Fig 6 ). These bands were excised from the gel and
ligated into either pcDNA3.1.V5/His or pcDNA3.1.V5.TGA.
Identification of Recombinants
Following ligation and transformation of the ligation products, the appropriate
clones were identified by restriction enzyme analysis. Schematic drawings of the
pcDNA3.1.MORl ,V5, pcDNA3 .1 .p2-AR.V5 and pcDNA3 . 1 .p2-AR vectors illustrating
the restriction enzyme sites used in the analysis are shown in Figure 7.
Clones for pcDNA3.1.MORl.V5 were identified initially by two criteria: the
presence of a unique EcoR I site in the insert DNA and the DNA fragment pattern
resulting from double digestion with Kpn I and Xba I. pcDNA3.1.MORl.V5 linearized
by EcoR I digestion was expected to be 6809 bp, 1,381 bp longer than the linearized
pcDNA3.1.V5.TGA, due to the presence of the insert DNA. Digestion of
pcDNA3.1MORl.V5 with Kpn I an Xba I was expected to yield two fragments, one 5446
bp in size, the other 1363 bp in size. Of the 6 colonies tested, all were found to meet these
criteria and colony 5 was selected for further analysis (Fig 8 ).
Clones for pcDNA3 . 1 .p2-AR.V5 were initially identified by the presence of a
unique BstE II site, the presence of a unique EcoR V site and the pattern of fragments
obtained by double digestion with Kpn I and Xba I. Of the 20 colonies selected, only
colony 12 yielded a single band at the predicted size of 6800 bp after BstE II digestion
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(Fig 9A). Digestion of plasma DNA from this colony with EcoR V also yielded a single
fragment at 6800 bp while double digestion with Kpn I and Xba I yielded a 5446 base
pair fragment and a 1358 bp fragment, corresponding in size to the PCR product (Fig
9B).
Clones for pcDNA3 . 1 -P2-AR were initially identified by the presence of a 1438 bp
fragment (corresponding to the insert DNA) after EcoR I digestion. All of the 10 colonies
selected yielded a 5500 bp fragment and a 1438 bp fragment at predicted sizes (Fig 10).
Diagnostic Restriction Enzyme Analysis
The selected recombinants were further analyzed by restriction enzyme digestions
to confirm that the insert DNA was ligated in the forward orientation. Digestion of
pcDNA3.1.MORl.V5 with BamHI, BstB I, Hind III/EcoR I and Kpn I/Xba I yielded
fragments which were consistent with the insert DNA having the correct sequence and
orientation (Fig 11). Similarly, digestion of pcDNA3.1.p2-AR.V5 with BstE II, Sty I, and
Hind III/EcoR V yielded fragments which were consistent with the insert DNA having
the correct sequence and orientation (Fig 12). Digestion of pcDNA3 . 1 .p2 -AR with EcoR
V and BstE II/Not I yielded fragments which were consistent with the insert DNA having
the correct sequence and orientation (Fig 13).
Expression of Recombinant Proteins in AN3 CA Cells
AN3 CA cells are a human endometrial carcinoma cell line which was
originally derived from an undifferentiated metastatic endometrial carcinoma (Fogh et al.
1977). Morphologically, cultured AN3 CA cells display an epithelial-like appearance
under the light microscope. Under standard culturing conditions, the efficiency of
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transient transfection could reach 30-40%. Preliminary data in our lab has shown that
AN3 CA cells do not express endogenous gravin.
To confirm that GR81-5534 was transcribed in AN3 CA cells, cells transfected
with GR81-5534 were stained with either an and-V5 antibody or with monoclonal antigravin antibody Mab2B3-l.l and observed using a confocal microscope. Both antibodies
revealed strong signals at the membrane of those cells expressing the transgene (Fig 14).
In addition, both the anti-V5 antibody and a polyclonal anti-gravin antibody detected a
~300kDa band on western blots of the transfected cells (Fig 15, lane 1, 2). The molecular
weight of the bands was similar to that of the endogenous gravin detected in extracts
from SH-SY5Y cells (Fig 15, lane 3).
The epitope-tagged MOR and p2-AR were initially detected by staining with the
anti-V5 antibody. The fluorescent signal was localized at the surface of the transfected
cells in both cases (Fig 16). To further confirm that the full-length receptor transgenes
were transcribed, AN3 CA cells transfected with either the V5-tagged MOR or the V5tagged p2-adrenergic receptor vectors were double labeled using the anti-V5 monoclonal
antibody and either a polyclonal anti-MOR antibody or a polyclonal anti-p2-adrenergic
receptor antibody (Fig 17 & 18). The fluorescent labeling by the anti-V5 and anti
receptor antibodies showed extensive colocalization and this colocalization was
confirmed by image merging.
Although the anti-V5 antibody displayed primarily plasma membrane staining,
the anti-MOR and the anti-p2-AR antibodies revealed membrane staining and some
cytoplasmic staining. To test whether this cytoplasmic staining represented expression of
the transgene or endogenous expression of the receptors, non-transfected AN3 CA cells
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were stained using either the anti-MOR antibody, the anti-p2-AR antibody, or the antigravin antibody. Both the anti-MOR and the anti-p2-AR antibodies detected weak
cytoplasmic staining, indicating either non-specific staining by the polyclonal antibody or
a low level of endogenous expression of these receptors in AN3 CA cells (Fig 19A, B).
The non-transfected cells did not label for gravin (Fig 19C).
Coexpression of Gravin and Receptor Transgenes
To determine whether gravin would colocalize with MOR in AN3 CA cells, cells
co-transfected with GR81-5534 and pcDNA3.1.MORl.V5 were double labeled with the
anti-gravin antibody and the polyclonal anti-MOR antibody. Both antibodies displayed
strong membrane staining and the staining of gravin and MOR showed extensive
colocalization (Fig 20, A and B). This colocalization was further confirmed by image
merging. To confirm that overexpression of either one of these two proteins did not
induce the expression of the other, and to confirm that the antibodies did not cross-react
with the recombinant proteins, cells transfected with either GR-81-5534 alone or
pcDNA3.1.MORl.V5 alone were double labeled by both anti-gravin and anti-MOR
antibodies. In Figure 20C and D, the cells transfected with only pcDNA3.1.MORl.V5
showed only anti-MOR reactivity. There was no detectable anti-gravin reactivity in these
cells. In Figure 20E and F, the cells transfected with only GR81-5534 reacted with the
anti-gravin antibody, but not with the anti-MOR antibody.
In experiments in which AN3 CA cells were co-transfected with GR81-5534
and pcDNA3.1.p2-AR.V5, and double labeled with anti-gravin and anti-p2AR antibodies,
both antibodies labeled the membrane and displayed extensive colocalization (Fig 21, A
and B). In the cells transfected with pcDNA3.1.p2-AR.V5 only and double labeled with
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both the anti-gravin and the anti-p2-AR antibodies, the anti-p2-AR antibody labeled the
membrane but anti-gravin labeling was negative (Fig 21, C and D). In cells transfected
with GR81-5534 and double labeled with both antibodies, only the anti-gravin antibody
showed positive staining (Fig 21, E and F).
Effect of Agonist Treatment on Gravin and Receptor Distribution
To determine if agonist mediated internalization of the V5-tagged MOR was
accompanied by redistribution of gravin, AN3 CA cells cotransfected with MOR and
gravin vector constructs were treated with DAMGO and double labeled with anti-MOR
and anti-gravin antibodies. Before agonist treatment, anti-gravin and anti-MOR antibody
labeling colocalized at the plasma membrane (Fig 22, A-D). After 30 min DAMGO
treatment, anti-MOR antibody labeling displayed a distinct punctate pattern of
fluorescence in the perinuclear region of the cell (Fig 22, E and G). This change in antiMOR labeling occurred in both co-transfected cells and cells transfected only with the
MOR vector. On the other hand, the majority of anti-gravin labeling remained at the cell
membrane after agonist treatment, and there was no detectable colocalization between the
anti-gravin and the anti-MOR labeling (Fig 22, E, F, and H)
To determine whether redistribution of gravin occurs during agonist induced
internalization of the V5-tagged p2-AR, AN3 CA cells cotransfected with both gravin and
p2-adrenergic receptor vector constructs were treated with isoproterenol and double
labeled with anti-p2-AR and anti-gravin antibodies. In cells either co-transfected with
GR81-5534 and pcDNA3.1.p2-AR.V5 vectors or transfected with pcDNA3.1.p2-AR.V5
alone, anti-p2-AR labeling showed a distinct punctate pattern of fluorescence at the
perinuclear region after 30 min of isoproterenol treatment (Fig 23, E and G). In the
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cotransfected cells and the cells transfected with GR81-5534 alone, the anti-gravin
antibody detected primarily membrane staining before and after isoproterenol treatment,
indicating no change in gravin distribution in response to isoproterenol (Fig 23, F and H).
No detectable colocalization of antibody labeling was revealed in cells co-transfected
with GR81-5534 and pcDNA3 .LP 2-AR.V5 after isoproterenol treatment (Fig 23, E and
F).
To examine the possibility that the V5-epitope fused to the C-terminus of the p2AR might affect protein-protein interaction between gravin and the receptors, AN3 CA
cells cotransfected with the gravin construct and a p2-AR construct lacking the V5epitope were either treated with isoproterenol for 30 min or not treated and double
labeled with anti-gravin and anti-p2-AR antibodies. As can be been in Figure 24, the antigravin and anti-p2-AR labeling colocalized in the absence of isoproterenol (Fig 24, A-D).
After isoproterenol treatment, anti-P2-AR labeling was concentrated in a region adjacent
to the nucleus (Fig 24, E), while gravin labeling remained on the cell membrane (Fig 24,
F). Control cells transfected with the P2-adrenergic receptor construct alone displayed
redistribution of p2-adrenergic receptor after isoproterenol treatment (Fig 24, G), while
there was no redistribution of gravin in the cells transfected with the gravin construct
alone (Fig 24, H).
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Figure 1: Effect of retinoic acid on gravin expression in SH-SY5Y cells Western blot
analysis of gravin expression in SH-SY5Y cells treated with either 10 pM retinoic acid
(RA) or ethanol for 6 days, or no treatment. Gravin expression was detected by a
polyclonal anti-gravin antibody.
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Figure 2: Duration of retinoic acid treatment Western blot analysis of gravin
expression in SH-SY5Y cells treated with 10 pM retinoic acid for 0, 4, 6, 8 , 10, and 12
days. Gravin expression was detected by a polyclonal anti-gravin antibody.

8

250 kDa
160 kDa
105 kDa
75 kDa

6

4

0

(days)

46

Figure 3: Effect of retinoic acid on gravin expression in SH-SY5Y cells
Immunofluorescent analysis (The magnification of the images is 280X) of gravin (a)
without and (b) with 10 pM retinoic acid for 6 days. Gravin expression was detected by a
monoclonal anti-gravin antibody and stained by Cy3-conjugated secondary antibody.
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Figure 4: Gravin distribution in SH-SY5Y cells treated with retinoic acid for 6 days
Immunofluorescent image showing gravin distribution in SH-SY5Y cells treated with
retinoic acid for 6 days, (a, b): immuno fluorescent dye tends to be distributed along
margins of cell bodies (arrows) (1200X). (c): immuno fluorescent dye reveals puntate
staining at cell margins and the edges of neurites (arrows) (950X). (d):
immunofluorescent dye reveals puntate staining at the edges of neurites (arrows)
(2400X); insert showing more detail at higher magnification (5600X).
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Figure 5: Gravin and MOR or p2-AR double labeling in SH-SY5Y cells I. SH-SY5Y
cells were double labeled with (A) anti-MOR antibody and (B) anti-gravin antibody, and
the images were merged in (C). The distribution of the antigens was analyzed by confocal
microscopy. The green channel reflects MOR stained by FITC (A), while the red channel
reflects gravin stained by Cy3 (B). Note that there was both membrane staining and
cytoplasmic staining for MOR and there was partial co localization of gravin and MOR at
the cell margins. II. SH-SY5Y cells were double labeled with (A) anti-p2-AR antibody
and (B) anti-gravin antibody, and the images were merged in (C). The distribution of the
antigens was analyzed by confocal microscopy. The green channel reflects p2-AR stained
by FITC (A), while the red channel reflects gravin stained by Cy3 (B). Note that there
was both membrane staining and cytoplasmic staining for p2-AR and there was partial
colocalization of gravin and p2-AR at the cell margins. Bar=25jum

I. Double label gravin/p-opioid receptor

II. Double label gravin/p 2-adrenergic receptor
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Figure 6: DNA sequences amplified by PCR DNA sequence encoding human p-opioid
receptor and (32-adrenergic receptor was PCR amplified from messenger RNA isolated
from SH-SY5Y cells that: had been treated with retinoic acid for 6 days. The PCR product
was separated on a 1% agarose gel. The presence of the band at 1381 base pairs, 1358
base pairs and 1422 base pairs indicated the presence of the amplified p-opioid receptor
and two P2-adrenergic receptor sequences, respectively.
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Figure 7: Schematic drawing of (A) pcDNA3.1.MORl.V5, (B) pcDNA3.1.p2-AR.V5
and (C) pcDNA3.1.p2-AR including restriction enzyme sites.
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Figure 8: Screening for positive clones for pcDNA3.1.MORl.V5 DNA samples from 6
colonies were digested by either EcoR I or Kpn I/Xba I, and separated on 1% agarose gel
to screen the positive clones. The presence of one band at 6809 base pairs by EcoR I
digestion and two bands at 1363 base pairs and 5446 base pairs by Kpn I/Xba I digestion
indicated a positive clone.
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Figure 9: Screening for positive clones for pcDNA3.1.p2-AR.V5
(A) : DNA samples from 20 colonies (1-20) were digested by BstE II and separated on a
1% agarose gel. The presence of one band at ~6800 base pairs suggested a positive clone.

(B) : Colony 12 was further selected and digested by BstE II, EcoR V and Kpn I/Xba I.
The presence of one band at 6804 base pairs by EcoR V digestion, 1358 base pair larger
than the fragment of pcDNA3.1V5.TGA digested by EcoR V, and two bands at 1358
base pairs and 5446 base pairs by Kpn I/Xba I digestion confirmed the presence of the
insert DNA.
Lane 1: Molecular weight marker
Lane 2: BstE II digestion
Lane 3: EcoR V digestion
Lane 4: Kpn 1/ Xba I digestion
Lane 5: pcDNA3.1V5.TGA digested by EcoR V
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Figure 10: Screening for positive clones for pcDNA3.1.p2-AR DNA samples from 10
colonies (1-10) were digested by EcoR I and separated on a 1% agarose gel. The presence
of the band at 1438 base pairs suggested positive clones.
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Figure 11: Identification and orientation of insert DNA for pcDNA3.1.MORl.V5
DNA sample was digested by BamHI, BstBI, Hind III/EcoR I, and Kpn I/Xba I to
confirm the presence of the insert DNA and the orientation of the insert. The existance of
the band at 1363 base pairs by Kpn I/Xba I digestion, which is the same size as the band
obtained from the PCR product digested by Kpn I/Xba I, confirmed the presence of the
insert. The 6809 base pair fragment by BamHI digestion, 1363 base pairs larger than the
fragment of pcDNA3.1V5.TGA digested by BamHI, also confirmed the presence of the
insert. The smaller band at 383 base pair by BstBI digestion and the smaller band at 1272
base pairs by Hind III/EcoR I digestion indicated the right orientation of the insert DNA.
Lane 1: Molecular weight marker
Lane 2: BamHI digestion
Lane 3: BstBI digestion
Lane 4: Hindlll/EcoR I digestion
Lane 5: Kpn I/Xba I digestion
Lane 6: undigested supercoiled pcDNA3.1.MORl.V5
Lane 7: pcDNA3.1V5.TGA digested by BamHI
Lane 8: PCR amplified MORI sequence digested by Kpn I/Xba I

224

64

Figure 12: Identification and orientation of insert DNA for pcDNA3.1. p2-AR.V5 The
presence of the insert DNA was already confirmed by EcoR V and Kpn I/Xba I digestion.
The full-length recombinant DNA is 6804 base pairs, according to BstE II digestion. The
smaller band at 1224 base pairs by Hind III/EcorR V digestion and the migration pattern
of the Dde I and Sty I digestion fragments indicated the right orientation of the insert
DNA.

Lane 1: Molecular weight marker
Lane 2: Bst Eli digestion
Lane 3: Dde I digestion
Lane 4: Sty I digestion
Lane 5: Hind III/EcoR V digestion
Lane 6: undigested supercoiled pcDNA3.1. p2-AR.V5
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Figure 13 Identification and orientation of insert DNA for pcDNA3.1. p2-AR DNA
sample was digested by EcoR V and Not 1/ BstE II to confirm the presence of the insert
DNA and the orientation of the insert. The presence of the band at 217 base pairs by
EcoR V digestion and the presence of the band at 1130 base pairs by Not 1/ BstE II
digestion confirmed the presence and the right orientation of the insert DNA.
HMWM: High molecular weight marker
LMWM: Low molecular weight marker
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Figure 14: Immunofluorescence microscopy showing expression of the gravin fusion
protein in AN3 CA cells AN3 CA cells grown on glass coverslips were transiently
transfected with GR81-5534. The expression of gravin was identified by (A) anti-V5
antibody and (B) anti-gravin antibody. The distribution of gravin was analyzed by
confocal microscopy. Both anti-V5 and anti-gravin antibodies revealed strong
fluorescence at the cell margins. Bar=7.5^m
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Figure 15: Western blot analysis showing expression of gravin fusion protein in AN3
CA cells AN3 CA cells were transiently transfected with GR81-5534. The cells were
lysed and the expression of the gravin fusion protein was detected by either an anti-V5
antibody (lane 1) or a polyclonal anti-gravin antibody (lane 2) using enhanced
chemiluminnescence. The control experiment included cell lysate from SH-SY5Y cells
treated with retinoic acid for 6 days, and immunoblotted with the anti-gravin antibody
(lane 3).
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Figure 16: Immunofluorescence microscopy showing expression of MORI and p2adrenergic receptor fusion protein in AN3 CA cells AN3 CA cells grown on glass
coverslips were transiently transfected with (A) pcDNA3.1.MORl.V5 or (B)
pcDNA3.LP2-AR.V5. The expression and distribution of MOR or p2-AR were detected
by anti-V5 antibody and analyzed by confocal microscopy. The anti-V5 antibody
detected both fusion proteins at the membrane of the transfected cells. Bar=25/jm
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Figure 17: Immunofluoresence microscopy showing expression of the
pcDNA3.1.MORl.V5 transgene in AN3 CA cells AN3 CA cells grown on glass
coverslips were transiently transfected with pcDNA3.1.MORl.V5 and double labeled
with (A) an anti-MOR antibody and (B) an anti-V5 antibody, and the images were
merged in (C). The anti-MOR was detected by an FITC-conjugated secondary antibody
and revealed as green fluorescence under confocal microscopy (A). The anti-V5 antibody
was detected by a Cy3-conjugated secondary antibody and revealed as red fluorescence
under confocal microscopy (B). Both anti-V5 and anti-MOR antibodies revealed
membrane staining and image merging showed overlap of MORI and the V5-epitope
(C). Bar=25jum
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Figure 18: Immunofluoresence microscopy showing expression of the pcDNA3.1.p2AR.V5 transgene in AN3 CA cells AN3 CA cells grown on glass coverslips were
transiently transfected with pcDNA3.1. p2-AR.V5 and double labeled with (A) an antiP2-AR antibody and (B) an anti-V5 antibody, and the images were merged in (C). The
anti-p2-AR antibody was detected by an FITC-conjugated secondary antibody and
revealed as green fluorescence under confocal microscopy (A). The anti-V5 antibody was
detected by a Cy3-conjugated secondary antibody and revealed as red fluorescence under
confocal microscopy (B). Both anti-V5 and anti-p2-AR antibodies revealed membrane
staining and image merging showed overlap of p2-AR and the V5-epitope (C).
Bar=25/Mn

78

Figure 19: Immunofluorescence microscopy of anti-MOR, anti-p2-AR, and antigravin labeling in non-transfected AN3 CA cells AN3 CA cells were labeled with (A)
anti-MOR, (B) anti-p2-AR, or (C) anti-gravin antibodies and analyzed under confocal
microscopy. Bar=25jum
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Figure 20: Immunofluorescence microscopy showing colocalization of gravin and
MOR in AN3 CA cells AN3 CA cells were co-transfected with GR81-5534/
pcDNA3.1.MORl.V5 (A, B), transfected with pcDNA3.1.MORl.V5 alone (C, D), or
transfected with GR81-5534 alone (E, F). All the transfectants were double labeled with
anti-gravin and anti-MOR antibodies. The distribution of the antigens was analyzed by
confocal microscopy. The green channel reflects MORI stained by FITC (A, C, E), while
the red channel reflects gravin stained by Cy3 (B, D, F). Note the colocalization of gravin
and MORI at the cell margins. Bar=25jum
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Figure 21: Immunofluorescence microscopy showing colocalization of gravin and p2adrenergic receptor in AN3 CA cells AN3 CA cells were co-transfected with GR815534/ pcDNA3.1.p2-AR.V5 (A, B), transfected with pcDNA3.1 .P2-AR.V5 alone (C, D),
or transfected with GR81-5534 alone (E, F). All the transfectants were double labeled
with anti-gravin and anti-p2-AR antibodies. The distribution of the antigens was analyzed
by confocal microscopy. The green channel reflects P2-AR stained by FITC (A, C, E),
while the red channel reflects gravin stained by Cy3 (B, D, F). Note the colocalization of
gravin and p2-adrenergic receptor at the cell margins. Bar=25jUm
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Figure 22: Immunofluorescence microscopy showing the effect of DAMGO
treatment on MOR and gravin distribution in AN3 CA cells AN3 CA cells were co
transfected with GR81-5534/ pcDNA3.1.MORl.V5 (A, B, E, F), transfected with
pcDNA3.1.MORl.V5 alone (C, G), or transfected with GR81-5534 alone (D, H). The
cells were double labeled with anti-gravin and anti-MOR antibody before (A-D) and after
(E-H) 10 pM DAMGO stimulation for 30 min. The distribution of the antigens was
analyzed by confocal microscopy. The green channel reflects MOR stained by FITC (A,
C, E, G), while the red channel reflects gravin stained by Cy3 (B, D, F, FI). Note the
translocation of MOR, but not gravin, after DAMGO stimulation. Bar=25/Mn
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Figure 23: Immunofluorescence microscopy showing the effect of isoproterenol on
P2 -AR and gravin distribution in AN3 CA cells AN3 CA cells were co-transfected with
GR81-5534/ pcDNA3.1.p2-AR.V5 (A, B, E, F), transfected with pcDNA3.1 .p2-AR.V5
alone (C, G), or transfected with GR81-5534 alone (D, H). The cells were double labeled
with anti-gravin and anti~p2-AR antibody before (A-D) and after (E-H) 10 pM
isoproterenol stimulation for 30 min. The distribution of the antigens was analyzed by
confocal microscopy. The green channel reflects p2-AR stained by FITC (A, C, E, G),
while the red channel reflects gravin stained by Cy3 (B, D, F, H). Note the translocation
of p2-adrenergic receptor, but not gravin, after isoproterenol stimulation. Bar=25/.m
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Figure 24: Immunofluorescence microscopy showing the effect of isoproterenol on
untagged p2-AR and gravin distribution in AN3 CA cells AN3 CA cells were co
transfected with GR81-5534/ pcDNA3.1.p2-AR (A, B, E, F), transfected with
pcDNA3.1.p2-AR alone (C, G), or transfected with GR81-5534 alone (D, H). The cells
were double labeled with anti-gravin and anti-P2-AR antibody before (A-D) and after (EH) 10 pM isoproterenol stimulation for 30 min. The distribution of the antigens was
analyzed by confocal microscopy. The green channel reflects P2-AR stained by FITC (A,
C, E, G), while the red channel reflects gravin stained by Cy3 (B, D, F, H). Note the
translocation of p2-adrenergic receptor, but not gravin, after isoproterenol stimulation.
Bar=25/uin
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CHAPTER IV

DISCUSSION
The present study investigated the hypothesis that gravin interacts with p-opioid
receptors and (32-adrenergic receptors during agonist-induced receptor internalization.
Immunofluorescent microscopy and immunoblotting data showed that gravin was
upregulated by retinoic acid in SH-SY5Y cells and that gravin was localized at the cell
membrane. The present study, the first to describe the distribution of p-opioid receptor in
SH-SY5Y cells using immunofluorescent staining and the first to describe the expression
and distribution of P2-adrenergic receptor in SH-SY5Y cells, also revealed that gravin
partially colocalized with p-opioid receptor and P2-adrenergic receptor in these cells.
Recombinant gravin, p-opioid receptor, and p2-adrenergic receptor expressed in AN3 CA
cells also localized to the membrane of the transfected cells. Extensive colocalization of
gravin and p-opioid receptor or P2-adrenergic receptor was observed in each of the
cotransfected cells. Although the recombinant receptors underwent internalization after
agonist treatment, this was not accompanied by gravin redistribution.
The pattern of gravin expression in SH-SY5Y cells corresponded with that of popioid receptor. Western blot analysis and immunofluorescence microscopy revealed that
gravin expression was upregulated by retinoic acid treatment. Increased gravin
expression was observed after 4 days of retinoic acid treatment and reached the highest
levels at 6 to 8 days of treatment. This pattern of expression in response to retinoic acid
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was similar to that reported for p-opioid receptor in SH-SY5Y cells. It has been reported
that either retinoic acid or phorbol ester treatment resulted in a significant increase in the
number of p-opioid receptor without affecting the affinity of agonist binding in SHSY5Y cells (Zadina et al., 1993). Six days of retinoic acid treatment resulted in a -175%
increase in p-opioid receptor expression (Zadina et ah, 1994). Because of the large
amount of expression of p-opioid receptor in this cell line, SH-SY5Y cells have proven
useful as a model system for studying p-opioid receptor in terms of the acute action of
opiates, or desensitization, resensitization, or down-regulation of the receptor. The
similarity of the expression pattern between gravin and p-opioid receptor in response to
retinoic acid is consistent with the hypothesis that gravin interacts with p-opioid
receptors and provided the possibility to study gravin and p-opioid receptor interaction in
SH-SY5Y cells.
The distribution of gravin in retinoic acid treated SH-SY5Y cells is also
consistent with the hypothesis that gravin may regulate p-opioid receptor activity.
Immunofluorescence microscopy revealed that in addition to being present in the
cytoplasmic compartment, gravin was localized at the membrane of the cell bodies and
the neurites, consistent with the localization of gravin at the cell membrane in HEL and
human umbilical vein endothelial cells (Nauert et al., 1997; Grove et al., 2001). Given
that gravin is known to bind PKA and PKC, the membrane localization of this protein
suggests that it may be involved in membrane associated PKA and PKC signaling events.
At present, the specific PKA and PKC signaling events in which gravin might participate
are unknown. However, several studies indicate that p-opioid receptor activity is
regulated by PKA and PKC. For instance, Smart and Lambert (1995) reported that
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desensitization of p-opioid receptor in SH-SY5Y cells involved both PKA and PKC. In
addition, Kramer et al. (1999) showed that exposure of SH-SY5Y cells to DAMGO
elicited a pronounced translocation of PKC from cytosol to plasma membrane. Studies on
other cell lines have also indicated that phosphorylation by PKC is required for
desensitization and internalization of p-opioid receptor (Mestek, et al., 1995; Ueda et al.,
2001). The involvement of PKA and PKC in regulating p-opioid receptor, together with
the membrane localization of gravin in SH-SY5Y cells supports the hypothesis that
gravin might play a role in regulating p-opioid receptor function by recruiting both PKA
and PKC to the receptor.
Data arising from the colabeling of SH-SY5Y cells for gravin and p-opioid
receptors is also consistent with the idea that gravin may interact with p-opioid receptors.
Immunofluorescence microscopy of cells double labeled with anti-gravin and anti-MOR
antibodies revealed partial colocalization of gravin and p-opioid receptors at the cell
surface and in the cytoplasm. Immunofluorescence microscopy of colabeled cells
revealed two populations of p-opioid receptor labeling, one at the cell surface, and the
other within the cytoplasm. Several studies have demonstrated that p-opioid receptors are
localized at the cell membrane in different cell lines (Ueda et al., 2001; Stemini et al.,
1996; Ruiz-Gomez et al., 1997; Gagnon et al., 1998). However, immunofluorescence
microscopy data has not yet been published for SH-SY5Y cells. While the cytoplasmic popioid receptor labeling may represent non-specific antibody labeling, it may also
represent receptors undergoing intracellular trafficking.
Gravin also colocalized partially with [^-adrenergic receptors in retinoic acid
treated SH-SY5Y cells. Immunofluorescence microscopy showed anti-fVAR antibody
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labeling both at the membrane and in the cytoplasm. In addition, anti-p2-AR labeling
partially codistributed with the anti-gravin labeling. SH-SY5Y cells were colabeled for
gravin and (32-adrenergic receptor because recent reports indicating that gravin may
interact with p2-adrenergic receptor (Shih et al., 1999) raised the possibility that gravin
expression in these cells may be linked to p2-adrenergic receptor expression as well.
However, p2-adrenergic receptor had not been reported to be expressed in SH-SY5Y
cells. The presence of positive anti-P2-AR labeling in the cells and the fact that p2adrenergic receptor cDNAs were amplified by RT-PCR from SH-SY5Y mRNA in the
present study confirmed that P2-adrenergic receptor is expressed in SH-SY5Y cells.
Partial colocalization of the anti-P2-AR and anti-gravin label is consistent with previous
reports of gravin-P2-AR interactions (Shih et al., 1999) and suggests that any interactions
between gravin and GPCRs expressed in SH-SY5Y cells may involve P2-adrenergic
receptor as well as p-opioid receptor.
The interaction between gravin and p-opioid receptor or p2-adrenergic receptor
was also investigated in AN3 CA cells transfected with gravin and the receptor
constructs. Initial characterization of the transfected cells confirmed that the transgenes
were expressed. Not only did the protein specific antibodies react specifically with the
transgene, but the gravin, p-opioid receptor and p2-adrenergic receptor transgenes
expressed in the AN3 CA cells displayed membrane localization, consistent with the
distribution pattern in SH-SY5Y cells or other cell lines (Grove and Bruchey, 2001; Ueda
et al., 2001; Ruiz-Gomez et al., 1997). In the case of the gravin transgene, both the antigravin and the anti-V5 antibody labeling revealed concentration of the transgene at the
cell membrane. In addition, western blotting with both the anti-gravin antibody and the
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anti-V5 antibody detected bands in transfected AN3 CA cell extracts which were
approximately the same molecular weight as the endogenous gravin from SH-SY5Y
cells. In case of the p-opioid receptor and p2-adrenergic receptor transgenes,
immunofluorescence microscopy of transfected cells double labeled with the anti-V5
antibody and the receptor-specific antibodies showed colocalization of the epitope tag
and receptor labeling. These validate the use of these fusion proteins in the current study.
Extensive colocalization of gravin and p-opioid receptor or p2-adrenergic
receptor at the cell membrane was revealed in the cells cotransfected with both gravin
and the receptor protein vectors. This colocalization was not due to cross-reactivity of the
antibodies, because cells transfected with either one of the vectors were not recognized
by the antibody against the other protein. Studies of p2-adrenergic receptor regulation
demonstrated the involvement of gravin in the phosphorylation and internalization of the
p2-adrenergic receptor and suggested that gravin may act as a scaffold which recruits the
receptor, protein kinases, P-arrestin, and clathrin (Lin et al., 2000). The finding in the
current study that gravin and p2-adrenergic receptor colocalized is consistent with these
observations. It has been also reported that internalization of p-opioid receptor is Parrestin-dependent: and clathrin-dependent (Xiang et al., 2000), and involves
phosphorylation of the receptor by PKC (Ueda et al., 2001). This suggests that gravin
may be involved in this event, a hypothesis which is supported by the colocalization of
gravin and the p-opioid receptor.
Although gravin appeared to colocalized with the p-opioid receptor and p2adrenergic receptor transgenes in untreated cotransfected cells, agonist induced receptor
internalization was not accompanied by gravin internalization. After agonist treatment,
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the p-opioid receptor and p2-adrenergic receptor transgenes displayed significant
translocation from the cell membrane to the perinuclear location, indicating that the
receptors were responsive to the agonist and that the epitope did not affect receptor
trafficking. However, the majority of gravin remained on the cell membrane and no
detectable colocalization between gravin and the internalized receptors was observed.
The rapid internalization of p-opioid receptor and p2-adrenergic receptor has been
reported in other cell lines (Ueda et al., 2001; Stemini et al., 1996; Ruiz-Gomez et al.,
1997; Gagnon et al., 1998). The consistency between the current data and the data from
these other studies indicated that the receptors were functioning appropriately in the
cotransfected AN3 CA cells. The use of a p2-adrenergic receptor transgene lacking the
epitope tag ruled out the possibility that the epitope tag at the C-terminus of the receptor,
where the gravin binding site is located (Fan et al., 2001), might have disrupted proteinprotein interaction. Although the possibility still exists that the epitope tag at the Cterminus of gravin may have interfered with gravin binding to the receptor and that use of
an untagged gravin transgene might lead to an alternative result, the current data suggests
that the internalization of the receptors is not accompanied by gravin redistribution. In
addition, the finding that the receptors in the cells transfected with only the receptor
protein vectors still underwent significant internalization upon agonist stimulation
suggests that gravin might not be crucial for internalization of the receptors.
Although gravin did not colocalize with the p-opioid receptor or p2-adrenergic
receptor after agonist treatment, the possibility still exists that gravin may be functionally
related to the receptors during the internalization procedure. It has been reported that the
internalization of the receptor is a rapid event that happens within minutes after the
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agonist stimulation (Gagnon et al., 1998). If gravin interacts with the receptors either
prior to or immediately after agonist stimulation, but the interaction is not retained during
the internalization event, approaches other than immunofluorescent staining would be
necessary to investigate gravin-receptor interaction. For example, one approach would be
to use fluorescence resonance energy transfer (FRET) microscopy, a technique to study
the protein-protein interaction within the living cells (Periasamy A, 2001). Another
approach to study gravin-receptor interaction might include immunoprecipitation, which
has been used in other studies to successfully identify a gravin-P2-adrenergic receptor
interaction (Shih et al., 1999). A third approach might include two-hybrid system, which
has also proved to be a successful way to identify protein-protein interaction in other
studies (Li et al., 2001).
On the other hand, the lack of colocalization between gravin and p-opioid receptor
after agonist treatment could indicate that gravin may not interact with p-opioid receptor.
Such a conclusion would be consistent with the view of some investigators that PKA and
PKC may not play a primary role in regulating p-opioid receptor activity. For instance,
the initial effect of p-opioid receptor activation is to decrease cAMP level and decrease
PKA activity. Therefore, it is understandable that PKA may not be the initial kinase that
phosphorylates the receptor. Consistent with this is the finding by one group of
researchers that forskolin did not stimulate 8-opioid receptor phosphorylation in 293 cells
(Pei et al., 1995). This group also found that down-regulation of PKC expression failed to
affect agonist-induced receptor phosphorylation, indicating PKC did not play a primary
role in opioid receptor phosphorylation after agonist treatment (Pei et al., 1995). In
addition, although PKC has been shown to translocate from the cytosol to the cell
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membrane after DAMGO stimulation in SH-SY5Y cells, this translocation occured 2-6
hours after DAMGO treatment and PKC was postulated to contribute to the downregulation of the p-opioid receptor expression (Kramer et al., 1999). Another study on popioid receptor also indicated that the effect of PKC in regulating p-opioid receptor was a
long-term effect, which affected the mRNA level of the p-opioid receptor, rather than a
short-term effect, which affected the process of desensitization or internalization by
phosphorylation (Gies et ah, 1997). Given that receptor phosphorylation is the initial step
after the agonist stimulation and leads to the internalization of the receptor, a lack of PKA
and PKC involvement in this event could account for the finding in the current study that
gravin was not required for the internalization of the receptor. However, the role of PKA
and PKC in regulating opioid receptor desensitization and internalization remains
controversial and further studies will be required to resolve the role of these kinases in
receptor regulation.
The finding in the current study that gravin did not colocalize with the P2adrenergic receptor after the agonist treatment differs from what has been reported by
others. Through a series of studies, Malbon and colleagues have reported that gravin is
associate with P2-adrenergic receptor and plays a role in phosphorylation and
internalization of P2-adrenergic receptor after agonist treatment in A431 cells (Shih et al.,
1999; Lin et al., 2000). In part, the results in the current study may differ from those
reported by others because of differences between A431 cells and transfected AN3 CA
cells. It is well known that phosphorylation of P2-adrenergic receptors requires several
different kinase activities, including PKA and PKC activity. It has been reported that
there are 2 different isoforms of PKA and 10 different isoforms of PKC. To date, it is not
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clear which isoform(s) of PKA or PKC are responsible for p2-adrenergic receptor
phosphorylation in A431 cells. It is possible that different sets of protein kinase iso forms
may be expressed in different cell lines and those responsible for p2-adrenergic receptor
phosphorylation in A431 cells may not be expressed in AN3 CA cells to an appropriate
level. It is not clear whether the binding between gravin and PKA or PKC is isoformspecific and therefore the lack of specific isoform(s) of PKA or PKC may interfere with
the formation of a gravin-mediated p2-adrenergic receptor signal complex after agonist
stimulation. This possibility may be confirmed by identifying the PKA or PKC isoforms
expressed in A431 cells and comparing them to those expressed in AN3 CA cells.
Although it has been postulated that gravin may be a component of the
internalization mechanism for p2-adrenergic receptor (Lin et al., 2000), gravin was not
required for p2-adrenergic receptor internalization in the current study. This difference in
results may in part be due to diversity in the internalization mechanism among different
cell lines. For example, catalytically inactive G-protein coupled receptor kinase 2
dominant-negative mutants blocked m2 muscarinic acetylcholine receptor (m2 mAChR)
internalization in COS7 cells, but had no effect on m2 mAChR internalization in BHK-21
and HEK 293 cells (Tsuga et ah, 1994; Pals-Rylaarsdam et ah, 1995). Experiments
testing the effects of P-arrestin and dynamin dominant-negative mutants on the
internalization of the p2-adrenergic receptor indicated that P-arrestins specifically target
p2-adrenergic receptor for endocytosis via clathrin-coated vesicles (Zhang et ah, 1996).
However, whereas the p2-adrenergic receptors underwent rapid internalization in HEK
293 cells, they internalized poorly in COS7 cells even after overexpression of P-arrestin
(Zhang et ah, 1996). Menard et ah (1997) also found that the maximal extent of p2-
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adrenergic receptor internalization in response to agonist activation was markedly lower
in COS7 cells than in HEK 293. These observations indicate the internalization of the

Pa-

adrenergic receptor is regulated by the cellular environment in which the receptor is
expressed. Given these observations, it is possible that the internalization mechanisms in
A431 cells differ from those in AN3 CA cells so that gravin is required in one situation
but not in the other.
Although the current study did not identify the functional interaction of gravin
and p-opioid receptor and P2-adrenergic receptor, the recombinant protein system used in
AN3 CA cells provided a good model to further pursue this hypothesis due to the
appropriate recombinant protein distribution, expression, and receptor trafficking
observed in the transfected cells. Future studies may include the use of different
techniques, or possibly different cell lines to further identify gravin-receptor interaction
or other aspects of the receptor functions.
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